BCYC
Bicycle Therapeutics Ltd
3.90$
+2.1%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Bicycle Therapeutics Ltd (BCYC) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -50 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.4 | -7.3 | -5.3 | -4.7 | -8.9 | -5.2 | -7.6 | -11 | -5.0 | 21 | -12 | -10.0 | -17 | -14 | -12 | 22 | -10 | -26 | -23 | -5.0 | -30 | -46 | 34 | -1.0 | -47 | -71 | -45 | -40 | -9.4 | -87 | -73 | -71 | -19 | -66 | -50 | -206 | |
| 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.6 | 1.3 | 1.4 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.6 | 2.2 | 1.7 | 1.6 | 1.7 | 1.8 | -5.1 | 1.1 | 1.1 | -1.1 | |
| 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.3 | 0.9 | 0.8 | 1.1 | 2.1 | 1.3 | 1.5 | 1.6 | 3.8 | 2.6 | 2.7 | 3.0 | 10 | 5.7 | 5.4 | 5.5 | 9.0 | 8.2 | 7.4 | 7.8 | 9.3 | 9.3 | 9.2 | 10 | 9.6 | 9.4 | 8.8 | -28 | 6.9 | 6.4 | -5.7 | |
| -0.3 | 0.3 | 0.4 | – | 0.9 | 3.5 | 3.1 | 0.8 | 1.1 | 2.1 | 1.3 | 1.5 | 1.6 | 3.9 | 2.7 | 2.8 | 3.1 | 10 | 5.8 | 5.5 | 0.6 | 6.7 | 6.7 | 15 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.3 | -5.2 | -0.9 | 1.3 | -1.8 | -2.4 | -0.7 | -2.5 | -1.9 | 30 | -1.9 | -1.7 | -1.2 | -1.8 | 2.5 | 33 | 4.1 | -9.4 | -2.4 | 16 | -2.4 | -16 | 68 | 32 | -8.1 | -55 | -16 | 0.6 | 36 | -36 | -4.6 | -23 | 63 | -13 | -8.9 | 18 | |
| 0.9 | 0.3 | 0.4 | 0.1 | 0.4 | 0.4 | 0.5 | 0.3 | 0.4 | 0.3 | 0.3 | 0.1 | 0.5 | 0.6 | 0.2 | 0.2 | 1.1 | 4.7 | 9.7 | 2.9 | 1.4 | 2.1 | 0.3 | 0.5 | 0.1 | 0.0 | 0.4 | 0.4 | 0.4 | 0.6 | 0.5 | 0.7 | 1.8 | 0.7 | 0.3 | 3.4 | |
| -0.9 | -0.3 | -0.4 | -0.1 | -0.4 | -0.4 | -0.5 | -0.3 | -0.4 | -0.3 | -0.3 | -0.1 | -0.5 | -0.6 | -0.2 | -0.2 | -1.1 | -4.7 | -9.7 | -2.9 | -1.4 | -2.1 | -0.3 | -0.5 | -0.1 | 0.0 | -0.4 | -0.4 | -0.4 | -0.6 | -0.5 | -0.7 | -0.6 | -0.7 | -0.3 | -2.2 | |
| 0.0 | 0.0 | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | – | – | 26 | 1.3 | 59 | 58 | 58 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | – | – | 0.0 | 0.0 | – | – | 15 | 15 | 15 | 15 | 15 | 15 | – | – | – | – | – | – | – | – | – | – | – | – | – | -32 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | -0.2 | |
| 6.6 | 25 | 25 | 0.0 | 25 | 0.0 | 59 | -0.8 | 0.3 | 0.2 | 0.0 | 61 | 1.7 | 74 | 16 | 41 | 191 | 0.3 | -0.5 | -0.5 | 5.9 | 2.7 | 12 | 235 | 0.4 | 1.9 | 550 | -32 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | -0.1 | |
| 5.1 | -5.1 | -9.2 | -5.5 | 15 | -4.0 | 49 | -13 | -3.8 | 18 | -13 | 53 | -14 | 60 | 2.8 | 61 | 179 | -31 | -35 | -11 | -22 | -45 | 47 | 232 | -46 | -69 | 504 | -71 | -11 | -87 | -72 | -73 | -20 | -69 | -50 | -211 | |
| -2.2 | -7.5 | -5.7 | -4.8 | -9.3 | -5.6 | -8.1 | -11 | -5.4 | 21 | -13 | -10 | -17 | -14 | -13 | 22 | -12 | -31 | -32 | -7.8 | -32 | -49 | 34 | -1.5 | -47 | -71 | -45 | -40 | -9.8 | -87 | -73 | -72 | -17 | -67 | -50 | -206 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.